Therapeutic Advances in Psychopharmacology
Journal Highlights
- Launched in 2011
- Gold open access journal – all articles are made freely available online immediately upon publication
- Rigorous peer review
- Listed in PubMed and indexed in Web of Science and Science Citation Index Expanded (SCIE)
- Over 1 million full-text article views annually
Therapeutic Advances in Psychopharmacology (TPP) is a peer-reviewed open access journal which focuses on delivering the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of psychopharmacology. Please see the Aims and Scope for further information.
The journal is a member of the Committee on Publication Ethics (COPE).
Diversity, Equity and Inclusion Statement
Therapeutic Advances in Psychopharmacology (TPP) promotes inclusive, open science that reflects the disciplinary, human, and geographic diversity of the psychopharmacology community.
Diversity as a core value embodies inclusiveness, mutual respect, and multiple perspectives.
We welcome editors, editorial board members, peer reviewers and authors from all backgrounds, cultures, ethnicities, nationalities, races, religions, sexes, sexual orientations, gender identities, mental or physical (dis)abilities, ages, career stages, socioeconomic status or any other individual status.
We are committed to continually improving our editorial and review processes whilst playing our part in eradicating bias and inequality in all forms.
Submission information
Submit your manuscript today at https://mc.manuscriptcentral.com/tpp.
Please see the Submission Guidelines for more information on how to submit your article to the journal.
Open access article processing charge (APC) information
Publication in the journal is subject to payment of an article processing charge (APC). The APC serves to support the journal and ensures that all articles are freely accessible online in perpetuity under a Creative Commons licence.
The APC for this journal is currently $3,000 USD. The article processing charge for Plain Language Summary is $4,500 USD.
The article processing charge (APC) is payable when a manuscript is accepted after peer review, before it is published. The APC is subject to taxes where applicable. Please see further details here.
Contact
Please direct any queries to tpp@sagepub.co.uk
Therapeutic Advances in Psychopharmacology delivers the highest quality peer-reviewed open access articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of psychopharmacology. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in psychopharmacology, providing an online forum for rapid dissemination of recent research and perspectives in this area.
The editors welcome original research articles across all areas of psychopharmacology.
The journal is dedicated to publishing clinical research. We do not publish preclinical research, including basic laboratory research and animal studies.
Review articles include expert opinion/perspective reviews (including single-drug and drug class reviews), narrative reviews and therapeutic area reviews. Systematic reviews, meta-analyses, health economic and pharma-economic reviews are also welcomed. The appropriate EQUATOR Network reporting guidelines should be followed (e.g. CONSORT for randomized, controlled trials and PRISMA for systematic reviews/meta-analyses). The journal endorses the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment. The trial registry name and URL, and registration number must be included at the end of the abstract.
The journal adheres to a single-anonymised peer review process in which the reviewer's name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees.
| Professor David Taylor, PhD FRPharmS FRCPEdin FRCPsych(Hon) | Maudsley Hospital, London, UK & King’s College London, UK |
| Shasha Sharief | SAGE Publishing, London, UK |
| Shikha Tomar | SAGE Publishing, India |
| Doctor Mark Horowitz, MBBS, PhD | Research and Development Department at North East London NHS Trust, UK & Department of Psychiatry at University College London, UK |
| Professor James Rucker, MBBS MRCPsych PhD | King’s College London, UK |
| Professor Shuichi Suetani, MB ChB, PhD | Queensland Centre for Mental Health Research, Queensland, Australia |
| Professor Mark Taylor, MBBS; MD; FRCPE; FRCPsych; FRANZCP | Griffith University School of Medicine, Queensland, Australia |
| Professor Ursula Werneke, MD, MSc, PgDip (LSHTM), FRCPsych | Umea University, Umea, Sweden |
| Balwinder Singh, MD, MS | Mayo Clinic, Rochester, Minnesota, USA |
| Professor Mahavir Agarwal, MBBS, MD, PhD | University of Toronto, ON, Canada |
| Professor David Baldwin, MA, DM, FRCPsych, FRSA, FHEA | University of Southampton, UK |
| Professor Thomas Barnes, MB BS, MD, FRCPsych, DSc | Imperial College London, UK |
| Associate Professor Francesco Bartoli, MD, PhD | School of Medicine and Surgery, University of Milano-Bicocca, Italy |
| Jaden Brandt, BSc.Pharm, MSc, DipPH | University of Manitoba, Manitoba, Canada |
| Professor Antonio Bruno, MD, PhD | Department of Biomedical, Dental Sciences and Morpho-functional Imaging (BIOMORF), University of Messina, Messina, Italy |
| Professor Katharina Domschke, MA, MD, PhD | Universitätsklinikum Freiburg, Germany |
| Professor Adriana Feder, MD | Icahn School of Medicine at Mount Sinai, New York, NY, USA |
| Professor Paul Glue, MD, FRCPsych | University of Otago, Dunedin, New Zealand |
| Professor Gerhard Grobler, MBChB, PhD, MMed (Psychiatry) | Steve Biko Academic Hospital and University of Pretoria, South Africa |
| Professor Peter Haddad, MD, FRCPsych | Barwon Health, Geelong, Victoria, Australia; Deakin University, Geelong, Victoria, Australia |
| Professor Oliver Howes, BM, BCh, MA, MRCPsych, PhD, DM | King's College London, London, UK |
| Professor Eija Kalso, MD, DMed Sci, PhD | University of Helsinki, Finland |
| Professor Deanna L. Kelly, PharmD, BCPP | University of Maryland School of Medicine, Baltimore, MD, USA |
| Professor Tim Lambert, BSc MBBS PhD FRANZCP | Sydney Local Health District, University of Sydney, Collaborative Centre for Cardiometabolic Health in Psychosis (ccCHiP) |
| Professor Anne Lingford-Hughes, PhD | Imperial College London, London, UK |
| Professor Feng Liu, PhD | Tianjin Medical University General Hospital, Tianjin, China |
| Professor Roger S. McIntyre, MD, FRCPC | Professor of Psychiatry and Pharmacology, University of Toronto, Toronto, Canada |
| Professor Jelena Milic, MSc, PhD | National Institute of Public Health, University of Belgrade, Serbia |
| Professor Phil Mitchell, MB BS (Hons I; Syd), MD (UNSW), FRANZCP, FRCPsych | University of New South Wales, NSW, Australia |
| Professor Antônio Egidio Nardi, PhD | Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil |
| Doctor Maxine X. Patel ,MBBS, MSc, MD, FRCPsych | Oxleas NHS Foundation Trust & King's College London, UK |
| Doctor Carol Paton, BSc, DipClinPharm, FCMHP | Imperial College London, UK |
| Doctor Jill Rasmussen, MBChB, FRCGP, FFPM | psi-napse, Dorking, UK |
| Professor Suzanne Reeves, PhD | University College London, UK |
| Hitoshi Sakurai, MD,PhD | Kyorin University Faculty of Medicine, Japan |
| Professor Mary Seeman, OC, MDCM, DSc | University of Toronto, ON, Canada |
| Professor Dan Siskind, MBBS, MPH, PhD, FRANZCP | The University of Queensland, St Lucia, Queensland, Australia |
| Professor Stephen Stahl, MD, PhD | University of California, San Diego, CA, USA |
| Professor James Stone, MBBS, PhD, FRCPsych | University of Sussex, Brighton, UK & King's College London, UK |
| Professor John Strang, MBBS, MD, FRCPsych, FAcMedSci | King's College London, UK |
| Professor Rajesh Tampi, MD, MS | Yale School of Medicine, New Haven, CT, USA & Creighton University School of Medicine, Omaha, NE, USA |
| Professor Mauricio Tohen, MD, DrPH, MBA | The University of New Mexico, School of Medicine, Albuquerque, USA |
| Professor Michael Travis, MD | University of Pittsburgh, Pittsburg, PA, USA |
| Professor Hiroyuki Uchida, MD, PhD | Keio University Medical School, Tokyo, Japan |
| Professor Eduard Vieta, MD, PhD | University of Barcelona, Barcelona, Spain |
| Professor Nicola Warren, MBBS, PhD | University of Queensland, Australia |
| Stefano Barlati, MD | University of Brescia, Italy |
| Dr. Federico Manuel Daray, MD, PhD | The University of Buenos Aires, Argentina |
| Dr. Riccardo Guglielmo, MD, PhD | University of Genoa, Genoa, Italy |
| Andrew Chih Wei Huang, PhD | Fo Guang University, Taiwan |
| Giuseppe Lanza, MD PhD | University of Catania, Catania, Italy |
| Seth Davin Norrholm, PhD | Wayne State University School of Medicine, Detroit, USA |
| LAURA ORSOLINI, MD, MSc | Polytechnic University of Marche, Ancona, Italy |
| Seon-Cheol Park, MD, PhD | Hanyang University College of Medicine, Seoul, Republic of Korea |
| Abid Rizvi, MD | West Virginia university, Morgantown, West Virginia, USA |
| Amanda Sales, PhD | Universidade de São Paulo - USP, Brazil |
Manuscript Submission Guidelines: Therapeutic Advances in Psychopharmacology
This Journal is a member of the Committee on Publication Ethics.
Please read the guidelines below then visit the Journal’s submission site https://mc.manuscriptcentral.com/tpp to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned.
Only manuscripts of sufficient quality that meet the aims and scope of Therapeutic Advances in Psychopharmacology will be reviewed.
As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you.
- What do we publish?
1.1 Aims & Scope
1.2 Article types
1.3 Writing your paper - Editorial policies
2.1 Peer review policy
2.2 Authorship
2.3 Acknowledgements
2.4 Funding
2.5 Declaration of conflicting interests
2.6 Research ethics and patient consent
2.7 Clinical trials
2.8 Reporting guidelines
2.9 Data - Publishing policies
3.1 Publication ethics
3.2 Contributor's publishing agreement
3.3 Open access and author archiving - Preparing your manuscript
4.1 Formatting
4.2 Artwork, figures and other graphics
4.3 Supplementary material
4.4 Reference style
4.5 English language editing services - Submitting your manuscript
5.1 ORCID
5.2 Information required for completing your submission
5.3 Permissions - On acceptance and publication
6.1 Article fee
6.2 SAGE Production
6.3 Online First publication
6.4 Access to your published article
6.5 Promoting your article - Further information
Before submitting your manuscript to Therapeutic Advances in Psychopharmacology, please ensure you have read the Aims & Scope.
Therapeutic Advances in Psychopharmacology considers the following kinds of article for publication:
- Original Research Articles, describing new experimental findings, or analyses (e.g. post hoc, subgroup, meta-analysis where an overall statistic is derived).
- Review Articles. The Editors wish to encourage the following types of review, but request that authors contact them in advance:
(a) general reviews that provide a synthesis of an area that fits within the aims and scope of the journal;
(b) perspectives - brief overviews, which are 6-8 printed pages in length including references, that address important new areas of general interest;
(c) systematic reviews and meta-analyses - these should be reported according to the PRISMA reporting guidelines (please see section 2.8)
(d) critiques - focused and provocative reviews that are followed by a number of invited commentaries, with a concluding reply from the main author;
(d) structured case reports - outlining an interesting case, and including a full review of the pertinent literature and a section on implications for clinical care;
(e) case series studies or clinical series – descriptive study of a small group of patients (with the same disease or receiving the same treatment) including a full review of the pertinent literature and a section on implications for clinical care;
3. Letters to the Editor; these also include brief case reports. These should be as concise as possible and up to 1000 words.
The journal considers the results of rigorous, well-designed studies that demonstrate "no effect" or that fail to replicate previous work ("negative data") as important to the advancement of science. Therapeutic Advances in Psychopharmacology welcomes short reports on null or negative results as long as the papers are based on strong hypothesis testing.
The SAGE Author Gateway has some general advice and on how to get published, plus links to further resources.
1.3.1 Make your article discoverable
When writing up your paper, think about how you can make it discoverable. The title, keywords and abstract are key to ensuring readers find your article through search engines such as Google. For information and guidance on how best to title your article, write your abstract and select your keywords, have a look at this page on the Gateway: How to Help Readers Find Your Article Online.
The journal's policy is to obtain at least two independent reviews of each article. Therapeutic Advances in Psychopharmacology operates a conventional single-blind reviewing policy in which the reviewer's name is always concealed from the submitting author. Referees will be encouraged to provide substantive, constructive reviews that provide suggestions for improving the work and distinguish between mandatory and non-mandatory recommendations. All manuscripts accepted for publication are subject to editing for presentation, style and grammar. Any major redrafting is agreed with the author but the Editor's decision on the text is final.
As part of the submission process you will be asked to provide the names of 3 peers who could be called upon to review your manuscript. Recommended reviewers should be experts in their fields and should be able to provide an objective assessment of the manuscript. Please be aware of any conflicts of interest when recommending reviewers. Examples of conflicts of interest include (but are not limited to) the below:
- The reviewer should have no prior knowledge of your submission
- The reviewer should not have recently collaborated with any of the authors
- Reviewer nominees from the same institution as any of the authors are not permitted
You will also be asked to nominate peers who you do not wish to review your manuscript (opposed reviewers)
Please note that the Editors are not obliged to invite/reject any recommended/opposed reviewers to assess your manuscript.
The Editor or members of the Editorial Board may occasionally submit their own manuscripts for possible publication in the journal. In these cases, the peer review process will be managed by alternative members of the Board and the submitting Editor/Board member will have no involvement in the decision-making process.
Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors.
The list of authors should include all those who can legitimately claim authorship. This is all those who:
- Made a substantial contribution to the concept or design of the work; or acquisition, analysis or interpretation of data,
- Drafted the article or revised it critically for important intellectual content,
- Approved the version to be published,
- Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.
Authors should meet the conditions of all of the points above. When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.
Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.
All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.
Any acknowledgements should appear first at the end of your article prior to your Declaration of Conflicting Interests (if applicable), any notes and your References.
2.3.1 Writing assistance
Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance. It is not necessary to disclose use of language polishing services.
Therapeutic Advances in Psychopharmacology requires all authors to acknowledge their funding in a consistent fashion under a separate heading. Please visit the Funding Acknowledgements page on the SAGE Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
2.5 Declaration of conflicting interests
It is the policy of Therapeutic Advances in Psychopharmacology to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles.
Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’. For guidance on conflict of interest statements, please see the ICMJE recommendations here.
2.6 Research ethics and patient consent
Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki.
Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.
For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.
Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative.
Please also refer to the ICMJE Recommendations for the Protection of Research Participants.
All research involving animals submitted for publication must be approved by an ethics committee with oversight of the facility in which the studies were conducted. The journal has adopted the Consensus Author Guidelines on Animal Ethics and Welfare for Veterinary Journals published by the International Association of Veterinary Editors.
Therapeutic Advances in Psychopharmacology conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.
The relevant EQUATOR Network reporting guidelines should be followed depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed CONSORT flow chart as a cited figure and the completed CONSORT checklist should be uploaded with your submission as a supplementary file. Systematic reviews and meta-analyses should include the completed PRISMA flow chart as a cited figure and the completed PRISMA checklist should be uploaded with your submission as a supplementary file. The EQUATOR wizard can help you identify the appropriate guideline.
Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives.
SAGE acknowledges the importance of research data availability as an integral part of the research and verification process for academic journal articles.
Therapeutic Advances in Psychopharmacology requests all authors submitting any primary data used in their research articles alongside their article submissions to be published in the online version of the journal, or provide detailed information in their articles on how the data can be obtained. This information should include links to third-party data repositories or detailed contact information for third-party data sources. Data available only on an author-maintained website will need to be loaded onto either the journal’s platform or a third-party platform to ensure continuing accessibility. Examples of data types include but are not limited to statistical data files, replication code, text files, audio files, images, videos, appendices, and additional charts and graphs necessary to understand the original research. The editor may consider limited embargoes on proprietary data. The editor can also grant exceptions for data that cannot legally or ethically be released. All data submitted should comply with Institutional or Ethical Review Board requirements and applicable government regulations. For further information, please contact the editorial office at tpp@sagepub.co.uk
SAGE is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the SAGE Author Gateway.
3.1.1 Plagiarism
Therapeutic Advances in Psychopharmacology and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarised other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.
3.1.2 Prior publication
If material has been previously published it is not generally acceptable for publication in a SAGE journal. However, there are certain circumstances where previously published material can be considered for publication. Please refer to the guidance on the SAGE Author Gateway or if in doubt, contact the Editor at the address given below.
3.2 Contributor's publishing agreement
Before publication, SAGE requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement. SAGE’s Journal Contributor’s Publishing Agreement is an exclusive licence agreement which means that the author retains copyright in the work but grants SAGE the sole and exclusive right and licence to publish for the full legal term of copyright. Exceptions may exist where an assignment of copyright is required or preferred by a proprietor other than SAGE. In this case copyright in the work will be assigned from the author to the society. For more information please visit the SAGE Author Gateway.
3.3 Open access and author archiving
Therapeutic Advances in Psychopharmacology offers optional open access publishing via the SAGE Choice programme. For more information please visit the SAGE Choice website. For information on funding body compliance, and depositing your article in repositories, please visit SAGE Publishing Policies on our Journal Author Gateway.
4. Preparing your manuscript for submission
The preferred format for your manuscript is Word. LaTeX files are also accepted. Word and (La)Tex templates are available on the Manuscript Submission Guidelines page of our Author Gateway.
4.2 Artwork, figures and other graphics
For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit SAGE’s Manuscript Submission Guidelines.
This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc) alongside the full-text of the article. For more information please refer to our guidelines on submitting supplementary files.
Therapeutic Advances in Psychopharmacology adheres to the SAGE Vancouver reference style. View the SAGE Vancouver guidelines to ensure your manuscript conforms to this reference style.
If you use EndNote or Zotero to manage references, you can download the appropriate output style file to help format your references quickly.
4.5 English language editing services
Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using SAGE Language Services. Visit SAGE Language Services on our Journal Author Gateway for further information.
Therapeutic Advances in Psychopharmacology is hosted on SAGE Track, a web based online submission and peer review system powered by ScholarOne™ Manuscripts. Visit http://mc.manuscriptcentral.com/tpp to login and submit your article online.
IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have had an account created. For further guidance on submitting your manuscript online please visit ScholarOne Online Help.
As part of our commitment to ensuring an ethical, transparent and fair peer review process SAGE is a supporting member of ORCID, the Open Researcher and Contributor ID. ORCID provides a persistent digital identifier that distinguishes researchers from every other researcher and, through integration in key research workflows such as manuscript and grant submission, supports automated linkages between researchers and their professional activities ensuring that their work is recognised.
We encourage all authors to add their ORCIDs to their SAGE Track accounts and include their ORCIDs as part of the submission process. If you don’t already have one you can create one here.
5.2 Information required for completing your submission
You will be asked to provide contact details and academic affiliations for all co-authors via the submission system and identify who is to be the corresponding author. These details must match what appears on your manuscript. At this stage please ensure you have included all the required statements and declarations and uploaded any additional supplementary files (including reporting guidelines where relevant).
Please also ensure that you have obtained any necessary permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please see the Copyright and Permissions page on the SAGE Author Gateway.
6. On acceptance and publication
Unsolicited manuscripts submitted to Therapeutic Advances in Psychopharmacology are subject to an article fee of 2,000 USD/ (+VAT where applicable*) payable upon acceptance. These articles will be published under a Creative Commons Licence and will be made openly available.
Your SAGE Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will be sent by PDF to the corresponding author and should be returned promptly. Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate. Please note that if there are any changes to the author list at this stage all authors will be required to complete and sign a form authorising the change.
Online First allows final articles (completed and approved articles awaiting assignment to a future issue) to be published online prior to their inclusion in a journal issue, which significantly reduces the lead time between submission and publication. Visit the SAGE Journals help page for more details, including how to cite Online First articles.
6.4 Access to your published article
SAGE provides authors with online access to their final article.
Publication is not the end of the process! You can help disseminate your paper and ensure it is as widely read and cited as possible. The SAGE Author Gateway has numerous resources to help you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice. In addition, SAGE is partnered with Kudos, a free service that allows authors to explain, enrich, share, and measure the impact of their article. Find out how to maximise your article’s impact with Kudos.
Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the Therapeutic Advances in Psychopharmacology editorial office as follows:
For all commercial sales and sponsorship enquiries, including advertising, reprints and supplements, please contact:
Commercial Sales Team, London, UK Tel: +44 20 7336 1205 Email: reprints@sagepub.co.uk